Pretreatment molecular biology analysis on small size biopsies;Biologie moléculaire préthérapeutique sur prélèvements biopsiques de petite taille

Annales de Pathologie

Volumn 30, Issue 5 SUPPL.1, 2010, Pages

  Antoine, Martine ^a   Poulot, Virginie ^a   Colombat, Magali ^a   Fleury, Jocelyne ^a   Lacave, Roger ^a   Cadranel, Jacques ^a  

^a HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; BIOPSY; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METHODOLOGY; MOLECULAR DIAGNOSIS; PATHOLOGY;

BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MOLECULAR DIAGNOSTIC TECHNIQUES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79953758265     PISSN: 02426498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annpat.2010.07.041     Document Type: Conference Paper

References (19)

1. La Vecchia C., Bosetti C., Lucchini F., Bertuccio P., Negri E., Boyle P., et al. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 2010, 10:1093.
2. Molinie F., Velten M., Remontet L., Bercelli P. Réseau Francim. évolution de l'incidence du cancer bronchopulmonaire en France (1978-2000). Rev Mal Respir 2006, 23:127-134.
3. Rami-Porta R., Crowley J.J., Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009, 15:4-9.
4. Cadranel J, Beau-Faller M, Mauguen A, Lizard S, Madelaine J, Lansiaux A, et al. ASCO Meeting Abstracts May 20 2009:8079. Biological and clinical prognostic factors in patients with advanced non-small-cell cancer (NSCLC) treated by erlotinib: preliminary results of the ERMETIC cohort.
5. Survie attendue des patients atteints d'un cancer en France: état des lieux. INCa avril 2010; www.e-cancer.fr.
6. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101:13306-13311.
7. Janne P.A., Engelman J.A., Johnson B.E. Epidermal growth factor receptor mutations in Non Small-Cell-Lung Cancer: implications for treatment and tumor biology. J Clin Oncol 2005, 23:3227-3234.
8. Pallis A.G., Voutsina A., Kalikaki A., Souglakos J., Briasoulis E., Murray S., et al. "Classical" but not other mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer 2007, 97:1150-1156.
9. Wu J.Y., Wu S.G., Yang C.H., Gow C.H., Chang Y.L., Yu C.J., et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 2008, 14:4877-4882.
10. Nguyen K.S., Kobayashi S., Costa D.B. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor in non-small-cell-lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009, 10:281-289.
11. Maheswaran S., Sequist L.V., Nagrath L., Ulkus L., Brannigan B., Collura C.V., et al. Detections of mutations in circulating lung-cancer cells. N Engl J Med 2008, 359:366-377.
12. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
13. Soda M., Choi Y.L., Enomoto M., et al. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature 2007, 448:561-566.
14. Wislez M., Antoine M., Baudrin L., Poulot V., Neuville A., Pradere M., et al. Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer 2010, 37:604-610.
15. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007, 104:20932-20937.
16. Sasaki T., Rodig S.J., Chirieac L.R., Jänne P.A. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010, 46:1773-1780.
17. Patricia Rivera M., Mehta A.C. Initial diagnosis of lung cancer. ACCP Evidence-based Clinical Practice Guidelines (2nd ed.). Chest 2007, 132:131-148.
18. Hofman V., Ilie M., Gavric-Tanga V., Lespinet V., Mari M., Lassalle S., et al. Rôle du laboratoire d'anatomie pathologique dans l'approche préanalytique des examens de biologie moléculaire réalisés en pathologie tumorale. Ann Pathol 2010, 30:85-93.
19. Yu J., Kane S., Wu J., Benedettini E., Li D., Reeves C., et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009, 15:3023-3028.